Edition:
United States

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

58.50USD
15 Feb 2019
Change (% chg)

$1.54 (+2.70%)
Prev Close
$56.96
Open
$57.39
Day's High
$58.76
Day's Low
$56.95
Volume
243,734
Avg. Vol
261,033
52-wk High
$68.15
52-wk Low
$37.29

Chart for

About

FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.... (more)

Overall

Beta: --
Market Cap(Mil.): $4,359.11
Shares Outstanding(Mil.): 78.97
Dividend: --
Yield (%): --

Financials

  FGEN.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -1.92 -- --
ROI: -28.39 8.92 14.45
ROE: -58.84 10.08 15.96

China first to approve AstraZeneca, FibroGen anaemia drug

LONDON China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

Dec 18 2018

China first to approve AstraZeneca, FibroGen anaemia drug

LONDON, Dec 18 China has become the first country to approve a new anaemia drug from AstraZeneca and FibroGen, well before decisions by regulators in the United States or Europe.

Dec 18 2018

Boost for 'made in China' medicine as Chi-Med wins key approval

LONDON Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

Sep 05 2018

UPDATE 1-Boost for "made in China" medicine as Chi-Med wins key approval

* Green light shows growing strength of Chinese biotech (Updates with CEO interview, latest shares, background)

Sep 05 2018

Boost for "made in China" medicine as Chi-Med wins key approval

LONDON, Sept 5 Hutchison China MediTech has won Chinese approval for a closely watched new cancer drug in a significant boost for "made in China" medicine.

Sep 05 2018

Earnings vs. Estimates